Cyclo Therapeutics

Executive Summary

Cyclo Therapeutics is a clinical-stage biotechnology company developing cyclodextrin-based therapies for rare and neurodegenerative diseases. Its lead program targets Niemann-Pick Disease Type C (NPC), a fatal genetic disorder with no approved treatments. The company's intravenous formulation of hydroxypropyl-β-cyclodextrin (Trappsol®) is currently in a Phase 3 trial (TransportNPC) evaluating its efficacy and safety in NPC patients. Additionally, Cyclo is exploring the application of its platform in Alzheimer's disease, addressing significant unmet medical needs. As a private company, Cyclo relies on strategic partnerships and fundraising to advance its pipeline. The upcoming Phase 3 data readout for NPC represents a pivotal milestone for the company. Positive results could support a New Drug Application (NDA) submission and potentially offer the first approved therapy for NPC, a high-value orphan indication. However, the company faces risks common to clinical-stage biotechs, including trial execution, regulatory hurdles, and capital constraints. Given the strong unmet need and the potential for breakthrough therapy designation, Cyclo Therapeutics presents a compelling, albeit high-risk, opportunity in rare disease drug development.

Upcoming Catalysts (preview)

• 2027Phase 3 TransportNPC Trial Top-Line Data65% success
• 2028FDA Regulatory Submission for NPC (if data positive)40% success